Medtech Company, Strados Labs, Awarded National Science Foundation SBIR Phase II Grant

Strados Labs, a medical technology company harnessing the power of smart sensors, machine learning and proprietary algorithms to provide early detection and predictions of worsening respiratory diseases, announced today it has been awarded a two-year Small Business Innovation Research (SBIR) Phase II grant from the National Science Foundation (NSF) for $990,118.

“It’s such an honor to receive this grant from such a highly regarded agency as the National Science Foundation,” said Strados co-founder and CEO Nick Delmonico. “This is an exciting time for Strados and the work we do in predictive algorithms for cardiopulmonary events like heart failure, COPD exacerbation and asthma, to name a few.”

The Strados RESP smart sensor platform for respiratory health is the first technology of its kind, providing real-time access to key changes in lung acoustics and respiratory patterns that goes well beyond cough measurement.

This award comes on the heels of key commercial milestones, including a pre-series A funding round of $4.5M and receipt of a CE Mark at the end 2021. The funding will help to further validate the RESP platform, enhance algorithm performance and expand marketing claims of the platform to enable early and lower cost treatment of chronic cardiopulmonary conditions and infectious disease in remote care settings via telehealth.

Read the full article here.

Previous

Next